Drug Trial Radar · NCT05297045
A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
17
Actual
Start
Mar 29, 2022
Primary completion
May 30, 2023
Study completion May 30, 2023
Sponsor
- Lead sponsor
- Regor Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 study designed to evaluate the efficacy of daily (QD) oral RGT001-075 GLP1 receptor agonist relative to placebo after up to 16 weeks of double-blind treatment as determined by mean change from baseline in HbA1c in adult patients with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control with diet and exercise and stable metformin treatment.
Conditions
- Type 2 Diabetes Mellitus
Interventions
RGT001-075Drug
Oral GLP1 Receptor Agonist
PlaceboOther
Placebo comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c from baseline to end of treatment in the modified intent-to-treat populationTime frame: up to 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Axon Clinical Research
Doral, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.